跳至主要内容
临床试验/NCT05997875
NCT05997875
招募中
不适用

Transforming Hemodialysis-Related Vascular Access Education (THRiVE)

University of Pennsylvania2 个研究点 分布在 1 个国家目标入组 360 人2023年12月5日

概览

阶段
不适用
干预措施
Educational Materials
疾病 / 适应症
Chronic Kidney Disease
发起方
University of Pennsylvania
入组人数
360
试验地点
2
主要终点
Surgery for Creation of Hemodialysis Arteriovenous Access (Effectiveness outcome)
状态
招募中
最后更新
3个月前

概览

简要总结

The focus of this study is on vascular access for hemodialysis. This is a randomized clinical trial testing 3 educational approaches to help patients with advanced chronic kidney disease prepare for placement of hemodialysis vascular access. Study participants will each be assigned to one of the 3 approaches: 1) "Education", in which participants will be given a video and brochure that provide information about the types of vascular access and what can be expected before and after the vascular access is placed, 2) "Education-Plus", in which participants will be given the video and brochure and will also have sessions by telehealth with a motivational interviewing coach to provide additional support around vascular access placement, and 3) "Usual Care", in which participants will have the usual education provided by their kidney doctor and clinic staff just as if they were not in the study. Participants in all 3 groups will be asked to complete questionnaires by telephone and may be invited to be interviewed about their experience with the study intervention at the end of the study. Study participation will last for about 12 months, with most of the study activities taking place during the first 3 months.

注册库
clinicaltrials.gov
开始日期
2023年12月5日
结束日期
2027年9月30日
最后更新
3个月前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Laura Dember, MD

Professor of Medicine and Epidemiology

University of Pennsylvania

入排标准

入选标准

  • Age 18 years or older
  • Nephrology visit for chronic kidney disease during the last 18 months
  • Most recent eGFR less than or equal to 20 ml/min/1.73 m2 or 2-year Kidney Failure Risk Equation score greater than 40%
  • Documentation in the medical record or confirmation from the treating nephrologist of a patient-nephrologist discussion about hemodialysis

排除标准

  • Planning for peritoneal dialysis, preemptive transplant, or conservative management of kidney failure
  • Previous placement of an AV access
  • Prior appointment with surgeon for AV access evaluation or creation
  • Cognitive dysfunction or severe visual impairment that prevents use of the education materials
  • Does not speak either English or Spanish

研究组 & 干预措施

Education

干预措施: Educational Materials

Education

干预措施: Usual Care

Education

干预措施: Patient Lists for Clinicians: System-Level Intervention

Education-Plus

干预措施: Educational Materials

Education-Plus

干预措施: Motivational Interviewing

Education-Plus

干预措施: Usual Care

Education-Plus

干预措施: Patient Lists for Clinicians: System-Level Intervention

Usual Care

干预措施: Usual Care

Usual Care

干预措施: Patient Lists for Clinicians: System-Level Intervention

结局指标

主要结局

Surgery for Creation of Hemodialysis Arteriovenous Access (Effectiveness outcome)

时间窗: Within 12 months after randomization or before hemodialysis initiation, whichever comes first

The proportion of participants who have arteriovenous access creation surgery.

次要结局

  • Preparedness for Decision-Making (Effectiveness outcome)(12 weeks after randomization)
  • Reasons for Participation - qualitative reach assessment (Implementation outcome)(12-16 weeks after randomization)
  • Vascular Access Knowledge (Effectiveness outcome)(12 weeks after randomization)
  • Characteristics of Enrolled Participants - quantitative reach assessment (Implementation outcome)(Baseline)
  • Reasons Nephrologists Opt-Out on Behalf of Patients - qualitative reach assessment (Implementation outcome)(Up to 4 years after trial initiation (full duration of the trial))
  • Completed Appointment with Surgeon for Vascular Access Evaluation (Effectiveness outcome)(Within 12 months after randomization or before hemodialysis initiation, whichever comes first)
  • Imaging for Planning Arteriovenous Vascular Access Creation (Effectiveness outcome)(Within 12 months after randomization or before hemodialysis initiation, whichever comes first)
  • Usable Arteriovenous Vascular Access (Effectiveness outcome)(Up to 4 years after randomization (full duration of the trial))
  • Acceptability of Intervention Content, Delivery, and Accessibility - qualitative acceptability assessment (Implementation outcome)(12 to 16 weeks after randomization)
  • Chronic Kidney Disease Class Attendance - quantitative fidelity assessment (Implementation outcome)(Within 12 months)
  • Scheduled Appointment with Surgeon for Vascular Access Evaluation (Effectiveness outcome)(Within 12 months after randomization or before hemodialysis initiation, whichever comes first)
  • Decision Self-Efficacy (Effectiveness outcome)(12 weeks after randomization)
  • Characteristics of Eligible Patients - quantitative reach assessment (Implementation outcome)(Pre-Enrollment)
  • Characteristics of Participants who Withdraw from the Trial - quantitative reach assessment (Implementation outcome)(From eligibility until 12 months)
  • Participant Contact Attempts for Motivational Interviewing - quantitative barriers/facilitators assessment (Implementation outcome)(12 month period after randomization)
  • System-Level Barriers to Arteriovenous Access Creation From Clinical Staff Perspective - qualitative implementation/barriers assessment (Implementation outcome)(Up to 4 years after trial initiation (full duration of the trial))
  • Receipt of Educational Materials - quantitative fidelity assessment (Implementation outcome)(Within 12 weeks after randomization)
  • Completed Motivational Interviewing Sessions - quantitative fidelity assessment (Implementation outcome)(Within 12 months after randomization)
  • Characteristics of Participants who Complete the Trial - quantitative reach assessment (Implementation outcome)(12 months)
  • Declined Enrollment - quantitative reach assessment (Implementation outcome)(Pre-enrollment)
  • Acceptability Intervention Measure - quantitative acceptability assessment (Implementation outcome)(12 -16 weeks after randomization)
  • System-Level Barriers to Arteriovenous Access Creation From Participant Perspective - qualitative implementation/barriers assessment (Implementation outcome)(Within 12 months)
  • Viewing of Video - quantitative fidelity assessment (Implementation outcome)(Within 12 weeks after randomization)
  • Brochure Delivery Mode - quantitative barriers/facilitators assessment (Implementation outcome)(Within 12 weeks after randomization)
  • Video Delivery Mode - quantitative barriers/facilitators assessment (Implementation outcome)(Within 12 weeks after randomization)
  • Missed Motivational Interviewing Sessions - quantitative barriers/facilitators assessment (Implementation outcome)(12 month period after randomization)

研究点 (2)

Loading locations...

相似试验